Skip to search formSkip to main contentSkip to account menu

3 ML insulin degludec 200 UNT/ML Pen Injector [Tresiba]

Known as: INSULIN DEGLUDEC 200 U in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Tresiba], 3 ML Tresiba 200 UNT/ML Pen Injector, Tresiba 200 UNT/ML per 3 ML Pen Injector 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The objective in diabetes’ treatment is to bring the blood sugar levels at the control target, in order to reduce the incidence… 
Review
2017
Review
2017
Achieving good glycaemic control while avoiding hypoglycaemia, in order to delay or prevent the long term complications in… 
2015
2015
Aim : The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in… 
2015
2015
Geringes Hypoglykämierisiko Langwirksames Basalinsulin − Nächtliche Hypoglykämien sind potenziell lebensbedrohlich und beeintr… 
2013
2013
Insulin degludec (Tresiba®) is an ultra-long-acting insulin analogue that is also available as a coformulation (Ryzodeg®) with… 
2013
2013
L’insuline dégludec (Tresiba®) est une insuline basale donnant après injection sous-cutanée des multi-hexamères solubles, qui… 
2013
2013
Degludec (Tresiba®) ist ein Basalinsulin, das nach subkutaner Injektion lösliche Multi-Hexamere bildet. Diese formen ein Depot…